PL395510A1 - Szczepionka wirusowa przeciwko infekcji wirusowej lub wielonarządowemu poodsadzeniowemu zespołowi wyniszczającemu wywoływanemu przez PCV2, jej zastosowanie, zakaźny molekularny klon DNA PCV2 oraz zawierający go biologicznie funkcjonalny plazmid lub wektor wirusowy - Google Patents

Szczepionka wirusowa przeciwko infekcji wirusowej lub wielonarządowemu poodsadzeniowemu zespołowi wyniszczającemu wywoływanemu przez PCV2, jej zastosowanie, zakaźny molekularny klon DNA PCV2 oraz zawierający go biologicznie funkcjonalny plazmid lub wektor wirusowy

Info

Publication number
PL395510A1
PL395510A1 PL395510A PL39551002A PL395510A1 PL 395510 A1 PL395510 A1 PL 395510A1 PL 395510 A PL395510 A PL 395510A PL 39551002 A PL39551002 A PL 39551002A PL 395510 A1 PL395510 A1 PL 395510A1
Authority
PL
Poland
Prior art keywords
pcv2
viral
organ
dna clone
vector containing
Prior art date
Application number
PL395510A
Other languages
English (en)
Polish (pl)
Inventor
Xiang-Jin Meng
Martijn Fenaux
Patrick G. Halbur
Original Assignee
Iowa State University Research Foundation, Inc.
Virginia Tech Intellectual Properties, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iowa State University Research Foundation, Inc., Virginia Tech Intellectual Properties, Inc filed Critical Iowa State University Research Foundation, Inc.
Publication of PL395510A1 publication Critical patent/PL395510A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL395510A 2001-12-12 2002-12-11 Szczepionka wirusowa przeciwko infekcji wirusowej lub wielonarządowemu poodsadzeniowemu zespołowi wyniszczającemu wywoływanemu przez PCV2, jej zastosowanie, zakaźny molekularny klon DNA PCV2 oraz zawierający go biologicznie funkcjonalny plazmid lub wektor wirusowy PL395510A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34077501P 2001-12-12 2001-12-12
US42484002P 2002-11-08 2002-11-08
US10/314,512 US7276353B2 (en) 2001-12-12 2002-12-09 Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof

Publications (1)

Publication Number Publication Date
PL395510A1 true PL395510A1 (pl) 2011-12-19

Family

ID=27405726

Family Applications (3)

Application Number Title Priority Date Filing Date
PL374382A PL214803B1 (pl) 2001-12-12 2002-12-11 Zakazna chimerowa czasteczka kwasu nukleinowego cirkowirusa swini PCV1-2, sposób jej wytwarzania, zawierajacy ja plazmid lub wektor wirusowy i komórka gospodarza, oraz chimerowy cirkowirus swini, sposób wytwarzania immunogennego produktu polipeptydowego, szczepionka wirusowa i jej zastosowanie, zakazna odwrotna chimerowa czasteczka kwasu nukleinowego cirkowirusa swini PCV1-2
PL395510A PL395510A1 (pl) 2001-12-12 2002-12-11 Szczepionka wirusowa przeciwko infekcji wirusowej lub wielonarządowemu poodsadzeniowemu zespołowi wyniszczającemu wywoływanemu przez PCV2, jej zastosowanie, zakaźny molekularny klon DNA PCV2 oraz zawierający go biologicznie funkcjonalny plazmid lub wektor wirusowy
PL395509A PL215058B1 (pl) 2001-12-12 2002-12-11 Szczepionka wirusowa przeciwko infekcji wirusowej lub wielonarzadowemu poodsadzeniowemu zespolowi wyniszczajacemu wywolywanemu przez PCV2 oraz jej zastosowania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL374382A PL214803B1 (pl) 2001-12-12 2002-12-11 Zakazna chimerowa czasteczka kwasu nukleinowego cirkowirusa swini PCV1-2, sposób jej wytwarzania, zawierajacy ja plazmid lub wektor wirusowy i komórka gospodarza, oraz chimerowy cirkowirus swini, sposób wytwarzania immunogennego produktu polipeptydowego, szczepionka wirusowa i jej zastosowanie, zakazna odwrotna chimerowa czasteczka kwasu nukleinowego cirkowirusa swini PCV1-2

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL395509A PL215058B1 (pl) 2001-12-12 2002-12-11 Szczepionka wirusowa przeciwko infekcji wirusowej lub wielonarzadowemu poodsadzeniowemu zespolowi wyniszczajacemu wywolywanemu przez PCV2 oraz jej zastosowania

Country Status (30)

Country Link
US (1) US7276353B2 (enExample)
EP (5) EP3388515A1 (enExample)
JP (1) JP4623964B2 (enExample)
KR (1) KR101014544B1 (enExample)
CN (2) CN1620310B (enExample)
AT (1) ATE487490T1 (enExample)
AU (3) AU2002362147C1 (enExample)
BE (1) BE2011C008I2 (enExample)
BR (1) BRPI0214919B1 (enExample)
CA (2) CA2784260C (enExample)
CO (1) CO5590938A2 (enExample)
CY (3) CY1111167T1 (enExample)
DE (2) DE60238278D1 (enExample)
DK (3) DK2263689T3 (enExample)
ES (3) ES2694505T3 (enExample)
FR (1) FR11C0014I2 (enExample)
HR (3) HRP20140003B1 (enExample)
HU (5) HU230576B1 (enExample)
LT (1) LT2264050T (enExample)
LU (1) LU91814I2 (enExample)
ME (1) ME00126B (enExample)
MX (1) MXPA04005364A (enExample)
NL (1) NL300480I2 (enExample)
NZ (2) NZ533256A (enExample)
PL (3) PL214803B1 (enExample)
PT (3) PT2263689E (enExample)
RS (1) RS51288B (enExample)
SI (3) SI1487483T1 (enExample)
TW (1) TWI314580B (enExample)
WO (1) WO2003049703A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
CN1749397B (zh) * 2004-08-18 2010-12-08 金宁一 共表达猪圆环病毒及口蹄疫病毒的二联重组活载体疫苗
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
PT2281829E (pt) 2004-12-30 2015-02-18 Boehringer Ingelheim Vetmed Composições imunogénicas de pcv2 para utilização num método de prevenção de infecção de pcv2
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
CN1328373C (zh) * 2005-04-07 2007-07-25 南京农业大学 猪ⅱ型圆环病毒重组腺病毒
MX2007016083A (es) * 2005-06-24 2008-03-10 Intervet Int Bv Vacunas quimericas inactivadas y metodos relacionados de uso.
UA95458C2 (ru) * 2005-09-09 2011-08-10 Интервет Интернешонал Б.В. Вакцина против pcv-2 у mda-положительных поросят
CN102698263B (zh) 2005-12-29 2016-07-06 贝林格尔.英格海姆维特梅迪卡有限公司 多价pcv2免疫原性组合物和制备此类组合物的方法
ES2553254T3 (es) * 2005-12-29 2015-12-07 Boehringer Ingelheim Vetmedica, Inc. Uso de una composición inmunogénica de PCV2 para reducir los síntomas clínicos en cerdos
JP4625485B2 (ja) * 2006-09-29 2011-02-02 財団法人大阪産業振興機構 高病原性トリインフルエンザウイルスに対するモノクローナル抗体
EP2099927A4 (en) * 2006-11-22 2010-05-05 Boehringer Ingelheim Vetmed Methods of reducing porcine circovirus-associated disease outbreaks
EP2101815A4 (en) 2006-12-11 2010-10-06 Boehringer Ingelheim Vetmed Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
RU2520087C2 (ru) 2006-12-15 2014-06-20 Бёрингер Ингельхайм Ветмедика, Инк. Лечение свиней с помощью антигена pcv2
EP1941903A1 (en) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
BRPI0812124A2 (pt) * 2007-05-30 2014-10-14 Wyeth Llc Poxviridae de guaxinim expressando genes de vírus suíno
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
KR101225304B1 (ko) * 2007-11-06 2013-01-22 와이어쓰 엘엘씨 마이코플라스마 하이오뉴모니아에 비독성 항원보강된 살아있는 백신
EP2225367A1 (en) * 2007-12-21 2010-09-08 Wyeth LLC Methods and compositions for immunizing pigs against porcine circovirus
WO2009088950A2 (en) * 2007-12-31 2009-07-16 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 virus like particle with foreign amino acid insertion
EP2242511A4 (en) * 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS
US20110033495A1 (en) * 2008-02-15 2011-02-10 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
CA2721513A1 (en) * 2008-04-16 2009-10-22 Virginia Tech Intellectual Properties, Inc. Chimeric porcine circovirus pcv2gen-1rep and uses thereof
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
ES2773722T3 (es) 2010-03-16 2020-07-14 Virginia Tech Intellectual Properties Inc Vacuna de circovirus porcino quimérico atenuado vivo
TWI508974B (zh) 2010-12-22 2015-11-21 Sbc Virbac Ltd 豬第二型環狀病毒(Porcine Circovirus Type 2)、含彼之免疫組合物、檢測套組及其應用
EP2660356A4 (en) 2010-12-28 2014-07-09 Jx Nippon Oil & Energy Corp DEVICE FOR HYDROGENATING ORGANIC COMPOUNDS AND HYDROGENATION METHODS
HUP1100470A2 (en) * 2011-08-30 2013-03-28 Mezoegazdasagi Biotechnologiai Kutatokoezpont Nanoparticle-based veterinary vaccine
UA113192C2 (xx) 2011-12-06 2016-12-26 Імуногенна композиція проти цирковірусу свиней типу 2 (pcv2)
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
KR102217387B1 (ko) * 2013-03-11 2021-02-19 주식회사 중앙백신연구소 재조합 효모 전세포(yeast whole cell)을 이용한 돼지 써코바이러스(PCV2) 서브유닛 백신과 그의 제조 방법
BR112016006192A2 (pt) 2013-09-25 2017-09-26 Zoetis Services Llc composição de vacina de divergente de pcv2b e métodos de uso
MX373884B (es) 2013-10-02 2020-03-26 Boehringer Ingelheim Animal Health Usa Inc Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta.
CN103602759B (zh) * 2013-11-22 2015-09-23 福建省农业科学院畜牧兽医研究所 一种区别鸭圆环病毒和鹅圆环病毒的pcr-rflp方法
BR112016012435A8 (pt) 2013-12-03 2018-01-30 Intervet Int Bv vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
EP3426293A4 (en) * 2016-03-07 2019-10-30 Virginia Tech Intellectual Properties, Inc. CHIMERIC VACCINES AGAINST PORCINE CIRCOVIRUS TYPE 2 (PCV2)
CN106497892A (zh) * 2016-09-07 2017-03-15 扬州大学 带KT3标签的重组病毒rPCV2‑KT3的构建方法
AU2019242601B2 (en) 2018-03-26 2025-12-04 Boehringer Ingelheim Animal Health USA Inc. Method of producing an immunogenic composition
CN112898435B (zh) * 2021-01-14 2023-03-31 山西农业大学 一种可溶性融合蛋白DT390-Cap及其制备方法与应用
AU2024266173A1 (en) 2023-05-03 2025-12-11 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition useful for self-administration by pigs
AR132582A1 (es) 2023-05-03 2025-07-16 Boehringer Ingelheim Vetmedica Gmbh Método para inducir una respuesta inmunitaria
US20250332242A1 (en) 2024-04-30 2025-10-30 Zoetis Services Llc Porcine endogenous retrovirus (perv)-free porcine circovirus type 2d-based vaccines and methods of use
US20250332243A1 (en) 2024-04-30 2025-10-30 Zoetis Services Llc Methods of manufacturing porcine endogenous retrovirus (perv) free animal health vaccines

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
FR2769321B1 (fr) 1997-10-03 2001-10-26 Merial Sas Nouveaux circovirus porcins, vaccins et reactifs de diagnostics
FR2781159B1 (fr) 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
WO1999029717A2 (en) * 1997-12-11 1999-06-17 University Of Saskatchewan Postweaning multisystemic wasting syndrome virus from pigs
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
FR2769322B1 (fr) 1997-10-03 2002-03-08 Merial Sas Nouveaux circovirus porcins, vaccins et reactifs de diagnostic
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
AU770002B2 (en) 1998-03-13 2004-02-12 University Of Georgia Research Foundation, Inc., The Vaccines against circovirus infections
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
CA2413265A1 (en) 2000-05-03 2001-11-08 University Of Guelph Porcine adenovirus type 5 vector and vaccine
PL360096A1 (en) 2000-05-24 2004-09-06 Merial Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
JP2004503234A (ja) 2000-06-15 2004-02-05 パーデュー・リサーチ・ファウンデーション ブタの先天性振せん用ワクチン
DE10044648A1 (de) 2000-09-08 2002-03-21 Aventis Behring Gmbh Verfahren zur Vermehrung oder zur Entfernung von Cirocoviren aus biologischem Material
US6794163B2 (en) 2001-03-27 2004-09-21 University Of Saskatchewan Methods to culture circovirus
AUPR567401A0 (en) 2001-06-14 2001-07-12 University Of Melbourne, The Circovirus vaccines

Also Published As

Publication number Publication date
BE2011C008I2 (enExample) 2022-02-02
EP2264050A3 (en) 2011-04-20
CN1620310B (zh) 2014-11-26
CN103536911B (zh) 2019-09-13
DE60238278D1 (de) 2010-12-23
DK2263689T3 (en) 2015-02-02
EP2263689A2 (en) 2010-12-22
DE122011100001I1 (de) 2011-09-08
SI1487483T1 (sl) 2011-03-31
US20030170270A1 (en) 2003-09-11
KR20040086243A (ko) 2004-10-08
EP1487483A2 (en) 2004-12-22
EP1487483A4 (en) 2006-02-15
PL374382A1 (en) 2005-10-17
HU228584B1 (en) 2013-04-29
HUP0501000A2 (en) 2007-12-28
HUP1300097A2 (en) 2007-12-28
PT2264050T (pt) 2018-11-21
CN1620310A (zh) 2005-05-25
LU91814I2 (fr) 2011-07-04
AU2002362147A1 (en) 2003-06-23
EP2263690A3 (en) 2011-06-08
CN103536911A (zh) 2014-01-29
ES2529726T3 (es) 2015-02-25
EP2264050A2 (en) 2010-12-22
AU2011200843A1 (en) 2011-03-17
WO2003049703A8 (en) 2005-12-01
HRP20140002B1 (hr) 2020-10-16
PL215058B1 (pl) 2013-10-31
FR11C0014I1 (enExample) 2011-06-17
HRP20040626B9 (hr) 2016-09-23
RS51704A (sr) 2006-10-27
EP2263689A3 (en) 2011-04-20
US7276353B2 (en) 2007-10-02
SI2264050T1 (sl) 2018-12-31
HRP20140002A2 (hr) 2014-11-07
AU2002362147C1 (en) 2012-05-17
NZ567688A (en) 2009-09-25
PT1487483E (pt) 2011-02-10
LT2264050T (lt) 2018-11-26
EP3388515A1 (en) 2018-10-17
HRP20140003A2 (hr) 2014-11-07
HUS2100036I1 (hu) 2021-09-28
BR0214919A (pt) 2006-05-30
ME00126B (me) 2010-10-10
HU231018B1 (hu) 2019-11-28
MXPA04005364A (es) 2004-09-27
BRPI0214919B1 (pt) 2015-09-15
PL395509A1 (pl) 2011-12-19
NZ533256A (en) 2008-06-30
EP2263690A2 (en) 2010-12-22
ES2694505T3 (es) 2018-12-21
JP4623964B2 (ja) 2011-02-02
ES2355814T3 (es) 2011-03-31
TWI314580B (en) 2009-09-11
PT2263689E (pt) 2015-02-13
AU2002362147B2 (en) 2008-03-13
CA2469599C (en) 2012-10-23
TW200307042A (en) 2003-12-01
MEP17708A (bs) 2010-06-10
CA2469599A1 (en) 2003-06-19
CY1121112T1 (el) 2019-12-11
FR11C0014I2 (fr) 2022-03-11
HK1151988A1 (en) 2012-02-17
DK1487483T3 (da) 2011-02-21
EP1487483B1 (en) 2010-11-10
HRP20040626A2 (en) 2006-03-31
AU2008202333A1 (en) 2008-06-19
PL214803B1 (pl) 2013-09-30
HU230576B1 (hu) 2017-01-30
CA2784260A1 (en) 2003-06-19
HU231162B1 (hu) 2021-05-28
HRP20040626B1 (hr) 2016-08-26
RS51288B (sr) 2010-12-31
HRP20140003B1 (hr) 2020-10-16
WO2003049703A3 (en) 2004-09-30
EP2263689B1 (en) 2014-11-12
CY1111167T1 (el) 2014-04-09
AU2008202333B2 (en) 2010-11-25
AU2011200843B2 (en) 2012-01-19
DK2264050T3 (en) 2018-12-03
CY2011004I1 (el) 2014-04-09
EP2264050B1 (en) 2018-08-08
CY2011004I2 (el) 2015-10-07
WO2003049703A2 (en) 2003-06-19
JP2005511075A (ja) 2005-04-28
KR101014544B1 (ko) 2011-02-16
ATE487490T1 (de) 2010-11-15
CA2784260C (en) 2016-05-17
NL300480I2 (enExample) 2016-11-01
CO5590938A2 (es) 2005-12-30
SI2263689T1 (sl) 2015-03-31

Similar Documents

Publication Publication Date Title
PL395510A1 (pl) Szczepionka wirusowa przeciwko infekcji wirusowej lub wielonarządowemu poodsadzeniowemu zespołowi wyniszczającemu wywoływanemu przez PCV2, jej zastosowanie, zakaźny molekularny klon DNA PCV2 oraz zawierający go biologicznie funkcjonalny plazmid lub wektor wirusowy
WO2005092069A3 (en) Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
HUP0102770A2 (hu) Sertésircovírus-antigént és sertésparvovírus-antigént tartalmazó vakcina
DK1037909T3 (da) Postweaning multisystemisk wasting-syndromvirus (PMWS) fra svin
CA2305623A1 (fr) Circovirus porcins, vaccins et reactifs de diagnostic
EP4272728A3 (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
AU2009236669A1 (en) Chimeric porcine circovirus PCV2Gen-1Rep and uses thereof
AP2002002685A0 (en) Use of flavivirus for the expression of protein epitpoes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents
DE60238773D1 (de) Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
CY1116098T1 (el) Χιμαιρικοι μολυσματικοι κλωνοι dna του κυκλοϊου των χοιρων και χρησεις εξ αυτων
ES2180448A1 (es) Superestructuras icosaedricas de vp2 del virus de la bursitis infecciosa (ibdv) y sus aplicaciones.

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)